The aim of this study was to explore evidence for association of target pharmacology of Glo1 inducer, tRES-HESP, to clinical variables of insulin resistance, dysglycemia, blood pressure, dyslipidemia, and low-grade inflammation assessed in the HATFF study—including established mediators of insulin resistance, thioredoxin interacting protein (TXNIP), and tumor necrosis factor-α. The gene discussed is TXNIP; the disease is metabolic syndrome.